Q3 2017 13F Holders as of 30 Sep 2017
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
77M
-
Number of holders
-
49
-
Total 13F shares, excl. options
-
13.1M
-
Shares change
-
-177K
-
Total reported value, excl. options
-
$114M
-
Value change
-
-$1.66M
-
Number of buys
-
22
-
Number of sells
-
-16
-
Price
-
$8.74
Significant Holders of Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) as of Q3 2017
56 filings reported holding CLSD - Clearside Biomedical, Inc. - Common Stock, $0.001 par value as of Q3 2017.
Clearside Biomedical, Inc. - Common Stock, $0.001 par value (CLSD) has 49 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 13.1M shares
of 77M outstanding shares and own 17% of the company stock.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (2.98M shares), Cormorant Asset Management, LLC (1.94M shares), BlackRock Inc. (1.36M shares), FMR LLC (981K shares), Rock Springs Capital Management LP (935K shares), Hillhouse Capital Management, Ltd. (900K shares), VANGUARD GROUP INC (720K shares), PERCEPTIVE ADVISORS LLC (620K shares), FIRST MANHATTAN CO (350K shares), and SPHERA FUNDS MANAGEMENT LTD. (300K shares).
This table shows the top 49 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.